Conclusions: With a pooled prevalence of 3.4%, the burden of disease among the elderly due to severe AS is substantial.Under current indications,approx 290,000 elderly patients with severe AS are TAVR candidates.Nearly 27,000 patients become eligible for TAVR annually.
Background: Since commercialization in 2007, the number of transcatheter aortic valve replacement (TAVR) procedures has grown exponentially. Despite the encouraging results from randomized controlled trials and registries, there is anecdotal evidence that the utilization of TAVR varies markedly across Europe. We sought to examine the adoption of TAVR in Western Europe. Methods: The adoption of TAVR was investigated in 11 European countries: Germany, France, Italy, United Kingdom, Spain, Netherlands, Switzerland, Belgium, Portugal, Denmark, and Ireland. Data were collected from two sources: (1) lead physicians submitted nation-specific registry data; (2) an implantation-based TAVRmarket tracker. Population data were derived from European Union sources. TAVR penetration in each nation was determined as a measure of actual TAVR use relative to potential use. Results: Between 2007 and 2011, 34,317 patients underwent TAVR. Considerable variation in TAVR utilization existed across nations. Almost half of all implants were performed in Germany (45.9%), with Italy (14.9%) and France (12.9%) the next most frequent implanters. Ireland accounted for the smallest proportion of implants (0.4). There was wide variation in the number of TAVR implants per million of population. Germany (88.7) and Portugal (6.1) accounted for the highest and lowest number of implants per million in 2011, respectively (meanAEstandard deviation: 32.9 AE 24.9). The number of centers performing TAVR increased 9-fold from 37 in 2007 to 342 in 2011. On average, there were 0.9 AE 0.6 TAVR centers per million of population. The annual number of TAVR implants performed per center across nations also varied widely (range:10 -89). In 2011, we estimate that there were 28,400 living TAVR recipients and 158,371 potential TAVR candidates in the 11 study nations. The weighted average TAVR penetration rate was low: 17.9%. Germany (36.2%) and Portugal (3.4%) had the highest and lowest TAVR penetration rates, respectively. 2012 -2013 data will be available for presentation at TCT. Conclusions: Despite the rapid adoption of TAVR in Europe, our findings indicate that TAVR adoption varies markedly across Europe and remains greatly underutilized in most nations.
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Procedural results with the selfexpanding 31mm CoreValve aortic bioprosthesis in patients with large annuli Background: Due to its specific design the selfexpanding 31mm CoreValve prosthesis (for annulus diameters between 26 and 29 mm) with its 4 mm landing zone can be technically challenging. Thus the procedural results with this device might be different from the ones with the smaller sizes. In addition the radial force of the nitinol stent frame is larger in the 31mm device than in the smaller device sizes. Methods: We retrospectively analyzed the procedural results of the 50 (out of over 600) patients in whom we implanted a 31mm selfexpanding CoreValve bioprosthesis between 2011 and May 2013 and compared them to the 52 consecutive patients implanted with a 29 mm device within the same period. Procedural results were analyzed according to the VARC-criteria. Results: Patients with large annuli and the 31 mm prosthesis had significantly higher rates of postinterventional pacemaker implantations (34% vs 19% ; p¼0.02) despite similar implantation depths (6.9 mm vs. 6.6 mm ; p¼ns). Although not significant, there was a tendency towards increased rates of postinterventional aortic regurgitation of more than mild (AR> grade 1)(14% vs.8%; p¼ns). In contrast major vascular bleeding (2% vs. 2%), 30-day mortality (6% vs. 7.6%) and stroke/TIA (4% vs. 2 %) were not different between the two groups. Conclusions: Despite the technical challenges of the small (4 mm) landing zone, procedural results with the 31mm device were similar to those with the smaller sizes of the device. However, postinterventional pacemaker rates were significantly higher in the 31mm cohort despite comparable implantation depths, which might be the result of the specific design of the device with its increased radial force. tertile (T3) of cardiac biomarker elevation, compared with pts in the lowest tertile (T1), had similar all-cause mortality rate (DcTnI: T3: 7.1% % vs T1: 6.2%, p¼0.7934; DCKMB: T3: 12.3% vs T1: 6.5%, p¼0.0996) and cardiovascular mortality rate (DcTnI: T3: 3.6% vs T1: 3.5%, p¼0.9987; DCKMB: T3: 5.9% vs T1: 4.4%, p¼0.5629). At 1 year, although numerically higher in T3, there remained no significant difference between tertiles with respect to all-cause mortality (DcTnI: T3: 30.1% vs T1: 22.7%, p¼0.1849; DCKMB: T3: 29.3% vs T1: 24.8%, p¼0.3704) (figure 1) and cardiovascular mortality (DcTnI: T3: 16.8% vs T1: 14.9%, p¼0.7064; DCKMB: T3: 17.0% vs T1: 16.6%, p¼0.9925). At 1 year, improvement of the New York Heart Association (NYHA) functional class (DcTnI: p¼0.6599, DCKMB: p¼0.1734) and www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
